Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Although no cause of death or further details were given, the news comes months after Lynch announced he had been living with ...

In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) ...

Are you searching for effective medications to treat 'Alpha-1 Antitrypsin Deficiency'? This comprehensive guide provides the latest information on medications-both generic and branded-that are ...

The CRISPR gene editing company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

The biotech company tested its experimental treatment in patients with alpha-1 antitrypsin deficiency ... Wave Life Sciences is also planning to test higher doses with results expected in 2025.

based on alpha-1 antitrypsin protein from the plasma of healthy donors. Clinical testing suggests that Inhibrx’s drug could require dosing once every three or four weeks, compared to weekly with ...

Quantification of stool alpha-1 Antitrypsin (sAAT) excretion is established for estimation of enteric protein loss and assessment of disease activity. This study is to access the feasibility of ...